Indoleamine-2,3-dioxygenase (IDO) Inhibition With INCB024360 and Intraperitoneal Delivery of Allogeneic Natural Killer Cells for Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Epacadostat (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2; Natural killer cell therapy
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 23 Aug 2017 Status changed from suspended to completed.
- 12 Dec 2016 Status changed from recruiting to suspended.